OptiBiotix Health PLC (LON:OPTI) has signed an exclusive distribution agreement with Taipei-based nutraceuticals firm MAXCARE to commercialise its SlimBiome product in Taiwan.
The AIM-listed group said MAXCARE was “well placed to educate customers on the benefits and functionality SlimBiome can provide” and had a team of registered dieticians to support commercialisation, with market exclusivity to be linked to minimum sales targets being achieved.
WATCH: OptiBiotix Health CEO talks significant new China, Hong Kong and North America deals
In a statement, Thomas O'Hara, business development manager at OptiBiotix, said MAXCARE has placed an initial trial order on the signing of the agreement as a result of “early interest received from introducing SlimBiome to [its] customers”.
“We chose MAXCARE due to their experience in commercialising weight management ingredients and their understanding of the value proposition SlimBiome provides to their customers. Having a trained team of registered dieticians that can provide technical support allows them to clearly convey the benefits and value SlimBiome can add to a range of products”, O’Hara added.
OptiBiotix shares rose 2.7% to 57.5p in early trading on Monday.
--Adds share price--